Stockscreener 앱 받기
4.28
0.23%
-0.010
시장 영업 전:
4.20
-0.08
-1.87%
전일 마감가:
$4.29
열려 있는:
$4.28
하루 거래량:
69,594
Relative Volume:
1.34
시가총액:
$23.13M
수익:
$15.00M
순이익/손실:
$2.71M
주가수익비율:
3.3635
EPS:
1.2725
순현금흐름:
$-2.89M
1주 성능:
-8.15%
1개월 성능:
-9.51%
6개월 성능:
+9.74%
1년 성능:
-36.12%
1일 변동 폭
$4.1784
$4.34
1주일 범위
$4.1784
$4.69
52주 변동 폭
$3.645
$21.40
Neuphoria Therapeutics Inc Stock (NEUP) Company Profile
명칭
Neuphoria Therapeutics Inc
전화
781-439-5551
주소
100 SUMMIT DR, BURLINGTON
Compare NEUP vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NEUP
Neuphoria Therapeutics Inc
|
4.28 | 23.19M | 15.00M | 2.71M | -2.89M | 1.2725 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neuphoria Therapeutics Inc Stock (NEUP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-09-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-09-28 | 재확인 | Maxim Group | Buy |
| 2022-01-10 | 개시 | Berenberg | Buy |
| 2022-01-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-01-10 | 개시 | Evercore ISI | Outperform |
| 2022-01-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Neuphoria Therapeutics Inc 주식(NEUP)의 최신 뉴스
NEUP Q1 2026 Earnings: Surprise EPS Beat Highlights Cost Discipline Despite Pre-Revenue StatusFinal Results - newsline.com
Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings - TradingView
NEUP Q1 2026 Earnings: EPS Surprises with 90.9% Beat Amid No RevenueBook Value Growth - The Legal Advocate
NEUP Q1 2026 Earnings: Significant EPS Beat Amidst Revenue AbsenceCapex Guidance - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower as Consolidation Continues Near SupportFlat Correction - The Legal Advocate
Neuphoria Therapeutics (NEUP) Edges Lower Amid Consolidation Near SupportBollinger Band - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowed Loss Surprises as Pre-Revenue Stage ContinuesPreliminary Results - The Legal Advocate
NEUP Q1 2026 Earnings: Narrowing Losses Beat Estimates Sharp, Yet Shares SlipRevenue Guidance Update - The Legal Advocate
Neuphoria Therapeutics (NEUP) Holds Steady Near Support – Can the Range Hold?Fibonacci Arc - newsline.com
Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial - TipRanks
Neuphoria Therapeutics (NEUP) Slips Amid Sector Headwinds – Key Support Levels in FocusSize Factor - The Legal Advocate
Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish BreakoutKey Reversal Day - Newser
NEUP Q1 2026 Earnings: Wider-Than-Expected Loss Narrows Sharply as Clinical Pipeline Progress Drives Investor OptimismEPS Surprise History - The Legal Advocate
NEUP Q1 2026 Earnings: Steeper-Than-Expected Loss Narrowing Fuels Post-Report RallyEarnings Surprise Score - Newser
What Neuphoria Therapeutics (NEUP)'s +1.62% Jump Means for Investors 2026-05-21Wave Extension - The Legal Advocate
NEUP Stock Moves Higher as Traders Focus on Neuphoria’s Cash Runway - Bez Kabli
Neuphoria Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Why Neuphoria Therapeutics (NEUP) Just Dropped -6.89% — What to Watch 2026-05-17Real Trader Network - Newser
NEUP Downgraded by HC Wainwright & Co. -- Rating Updated to Neut - GuruFocus
Key facts: NEUP BNC210 Fails; SAD Halted, PTSD Paused; Q2 Loss $1.12 - TradingView
Neuphoria Therapeutics Inc expected to post a loss of $1.12 a shareEarnings Preview - TradingView
Deal Dispatch: GoPro Retains Houlihan Lokey In Strategic Review, Brookfield Buys World Freight Company, YesCare Corp. Bankruptcy - Benzinga
Neuphoria Therapeutics Inc. Q1 2026 10-Q Report: Financials, Risk Disclosures, and Strategic Outlook - Minichart
H.C. Wainwright Downgrades Neuphoria Therapeutics(NEUP.US) to Hold Rating - Moomoo
Neuphoria Therapeutics Inc. 3Q 2026: Revenue $0 EPS $(0.09) — 10-Q Summary - TradingView
Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
Neuphoria Therapeutics Inc. (NEUP) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
How Neuphoria Therapeutics (NEUP) performance compares to expectations (Slight Dip) 2026-05-11ETF Creation Redemption - Newser
NEUP Shares Rise Pre-Market As It Explores Strategic Alternatives, Including Potential Acquisition - MSN
How sustainable is Neuphoria Therapeutics (NEUP) earnings momentum | Q1 2026: Better Than Expected - newser.com
How Neuphoria Therapeutics (NEUP) adapts when conditions change (Smart Money Flows) 2026-05-05Senior Analyst Forecasts - newser.com
NEUP Neuphoria Therapeutics reports narrower than expected Q1 2026 loss, shares climb 2.65 percent in today’s trading.Verified Analyst Reports - newser.com
Whats the outlook for Neuphoria Therapeutics Incs sectorInsider Selling & High Yield Equity Trading Tips - baoquankhu1.vn
Decliners Report: Is Neuphoria Therapeutics Inc impacted by rising rates2026 Institutional Moves & Verified Entry Point Detection - baoquankhu1.vn
Neuphoria Therapeutics Inc. (NEUP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
New Highs: Whats the outlook for Neuphoria Therapeutics Incs sectorFed Meeting & Verified Momentum Stock Watchlist - baoquankhu1.vn
If You Invested $1,000 in Neuphoria Therapeutics Inc (NEUP) - Stock Titan
Earnings Report: Is Neuphoria Therapeutics Inc vulnerable to short sellers2026 Weekly Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Big Money Moves: Is Neuphoria Therapeutics Inc a good ESG investment2026 Technical Patterns & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Is Neuphoria Therapeutics (NEUP) Stock a Top Performer | Price at $4.36, Down 1.25%NHNL Divergence - newsline.com
Why Did NEUP Stock Surge 64% Today? - MSN
How does macroeconomics affect Neuphoria Therapeutics (NEUP) Stock | Price at $4.78, Up 1.27%Arms Index - The Legal Advocate
NEUP Stock Analysis: Neuphoria Therapeutics gains 7.04 percent to hit 4.41 mark - newsline.com
Fed Watch: Whats the outlook for Neuphoria Therapeutics Incs sectorQuarterly Market Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Aug Outlook: Is Neuphoria Therapeutics Inc a good ESG investment2026 Bull vs Bear & Daily Stock Momentum Reports - baoquankhu1.vn
Neuphoria Therapeutics Inc (NEUP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):